Sai Life Sciences partners with Mabtech to boost immunology research in the USSai Life Sciences partners with Mabtech to boost immunology research in the US

Introduction

Leading contract research organization announced a strategic collaboration to establish a Boston laboratory as a US execution hub for EYRA platform based immunology assay services.

Also Read: Highway Infrastructure starts toll operations at Kaza Fee Plaza on NH-16

Share price movement of Sai Life Sciences

On January 29, 2026, Sai Life Sciences Ltd opened at ₹847.90, up 0.07% from its previous close of ₹847.35. The stock reached a high of ₹852.75 (0.68%) and a low of ₹838.25. By 10:28 AM, it traded at ₹840.05, a 0.86% decrease, with a market cap of ₹17,744.45 crore.

Sai Life Sciences-Mabtech Collaboration Announced

Sai Life Sciences announced a strategic collaboration with Mabtech, establishing its Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA immunology research platform services globally.

Under the collaboration, Sai Life Sciences and Mabtech will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, using the EYRA platform at Sai Boston site.

The initiative aims to accelerate access to next-generation immune profiling capabilities for biopharma and biotech companies working in immuno-oncology, vaccines, inflammation, and cellular therapy through joint services and demonstrations programs.

Stock performance of Sai Life Sciences for Period of 1 week, 6 months, and 1 year

Over the past one week, Sai Life Sciences Ltd gained 2.61%. Over six months, the stock rose 7.56%, and over the past one year, it increased 26.0%.

Also Read: Suzlon Energy moves up 3% as company bags first 248.5 MW wind order from ArcelorMittal

Shareholding pattern of Sai Life Sciences

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	34.70%	34.90%	35.20%
FII	21.40%	22.50%	14.60%
DII	31.40%	29.90%	21.60%
Public	13%	12.70%	28.60%

About Sai Life Sciences

Sai Life Sciences Ltd (NSE: SAILIFE), founded in 1999, provides contract research, development, and manufacturing services for pharmaceutical and biotechnology companies globally.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs